MedTrace Logo

High-power Green-light Laser Endoscopic Submucosal Dissection for Non-muscle-invasive Bladder Cancer

NCT05290623 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2022-03-22

No results posted yet for this study

Summary

A retrospective study was designed in this study. The surgeon performed high-power green-light laser endoscopic submucosal dissection (HPL-ESD) for the treatment of primary non-muscle-invasive bladder cancer (NMIBC). This surgical treatment was novel and safety and efficacy of the treatment has not been established. We collected relative data in Shandong Provincial Hospital Affiliated to Shandong First Medical University from May 2018 to December 2020. Preoperative, intraoperative and postoperative clinical data were collected and analysed. The safety and efficacy of the novel surgical treatment were verified by the short-term and long-term clinical outcomes. Fifty patients with NMIBC were planed to be enrolled in the study.

Conditions

Sponsors & Collaborators

  • Shandong Provincial Hospital

    lead OTHER_GOV

Eligibility

Min Age
20 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2020-12-30
Completion
2022-03-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05290623 on ClinicalTrials.gov